Clinical trials: Streptococcus Pneumoniae Vaccines
Hepatitis A
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Three dose primary vaccination study of reactogenicity and immunogenicity in healthy infants between 6-12 weeks of age at the time of the first vaccination against Streptococcus pneumoniae.
- Trial name
- NCT00338351
- Testing
- Pneumococcal (vaccine)
- Where
- Chile
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in…
- Trial name
- NCT00366678
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine, Pentavac
- Where
- 45 sites in France
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Lupus Erythematosus, Systemic
Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus
The aim of this study is to compare the immunological efficacy of two pneumococcal vaccination strategies in patients with systemic lupus erythematosus (SLE) treated with corticosteroids associated or not with other…
- Trial name
- VACCILUP (NCT00611663)
- Testing
- Prevenar® and Pneumo23®
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Middle Ear Effusion, Tympanic Membrane Perforation
PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease
PneuMum is a randomised controlled trial that aims to find out if pneumococcal vaccination for Australian Indigenous mothers, in the last few months of pregnancy or at delivery, can prevent ear disease in infants.
- Conditions
- Middle Ear Effusion, Tympanic Membrane Perforation, Acute Otitis Media, Pneumococcal Infections
- Trial name
- NCT00310349
- Testing
- 23 valent pneumococcal polysaccharide vaccine
- Where
- Australia
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- Trial name
- NCT04382326
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 1,997 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Immunization
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
Primary Objectives: Assessed the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination Assessed the safety profile of the 3 SP0202 formulations…
- Trial name
- NCT04583618
- Testing
- Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb, Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI, Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII
- Where
- 17 sites in United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Sanofi
Infections, Streptococcal
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants
This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis…
- Trial name
- NCT00390910
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Infanrix hexa
- Where
- 8 sites in Greece, Spain
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract
The colonization of potential pathogenic bacteria in lower respiratory tract is thought to be accountable for acute exacerbation in subjects with moderate to severe COPD.
- Trial name
- PAEAN (NCT03449459)
- Testing
- oral probiotics, aerosol inhaled amikacin, combined vaccination
- Where
- 3 sites in China
- Volunteers
- 144 people
- Sponsor
- Shanghai Zhongshan Hospital
HIV, Pneumococcal Infections
Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults
Streptococcus pneumoniae is a cause of high morbidity and mortality in HIV-positive subjects, representing the leading etiological agent of severe bacterial pneumonia.
- Trial name
- NCT02357823
- Testing
- Evaluation of immunological response, Nasopharyngeal swabs analysis
- Where
- 2 sites in Italy
- Sponsor
- University of Siena
Pneumococcal Vaccines
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
- Trial name
- NCT00574548
- Testing
- 13 valent Pneumococcal Conjugate Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine
- Where
- 6 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
Pneumococcal Reference Standard
Serum 89 SF is a supply of serum that was collected from people who were vaccinated with the pneumococcal vaccine in the late 1980s. The supply of this serum is running low.
- Trial name
- NCT00479323
- Testing
- Pneumovax 23
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Streptococcus Pneumoniae
Costa Rica Epidemiological Study on S. Pneumoniae
Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia and pneumococcal meningitis among infants and children worldwide.
- Trial name
- NCT01308827
- Testing
- Blood culture, Other cultures per Clinical routine practice
- Where
- 5 sites in Costa Rica
- Volunteers
- 4,000 people
- Sponsor
- Instituto de Atención Pediátrica
PNC Vaccine, HIV-infected Pregnant Women
Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women
The purpose of this study was to determine the safety, reactogenicity, immunogenicity, transplacental antibody transfer and interference with infant responses to childhood vaccination of maternal vaccination with pneumococcal…
- Trial name
- NCT02717494
- Testing
- PPV-23, PCV-10, NaCl
- Where
- 8 sites in Brazil
- Volunteers
- 347 people
- Sponsor
- Westat
Nasopharyngeal Carriage, Children, Only
Nasopharyngeal Carriage of S. Pneumoniae
This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines…
- Conditions
- Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain
- Trial name
- NCT04460313
- Testing
- nasopharyngeal sample (mandatory), Stools collection or anorectal swab samples (optional), nasopharyngeal sample (optional)
- Where
- France
- Volunteers
- 29,360 people, healthy volunteers welcome
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne
Pneumococcal Infections
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae.
- Trial name
- 6114A1-4000-CN (NCT01193582)
- Testing
- Prevenar
- Where
- 5 sites in China
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China
Pneumococcal infection is a leading cause of death throughout the world and a major cause of pneumonia, bacteremia, meningitis, and otitis media.
- Trial name
- NCT01451086
- Testing
- vaccine made by Beijing Minhai Biotechnology Co., Ltd, vaccine made by Chengdu Institute of Biological Products
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccine, Streptococcus Pneumoniae
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
The French Public Health Council recommended pneumococcal vaccination combined strategy for all immunocompromised patients in 2012.
- Conditions
- Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin
- Trial name
- HEMATOVAC (NCT04460235)
- Testing
- Prevenar 13 + Pneumovax 23, PREVENAR20
- Where
- 7 sites in France
- Volunteers
- 160 people
- Sponsor
- Poitiers University Hospital
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate (Prevenar/Prevenar®, 7vPnC), when given…
- Trial name
- NCT00366340
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 51 sites in Germany
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccine-Preventable Diseases
Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity
Rationale Causing a wide range of infectious diseases, including pneumonia, otitis media and meningitis, S. pneumoniae represents an important global health problem.
- Trial name
- SEA (NCT06202703)
- Testing
- Pneumococcal Vaccine
- Where
- Netherlands
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center